Copyright © 2014 EnBiotix, Inc.. All Rights Reserved

EnBiotix Acquires Anti-Microbial Peptide Portfolio from AMP Therapeutics GmbH

PRESS RELEASE | CAMBRIDGE, Mass. and LEIPZIG, Germany (November 3, 2016) – EnBiotix, Inc., a product-focused bioengineering company leveraging systems and synthetic biology platforms to combat the global rise of drug-resistant and drug-tolerant bacterial infections, today announced the completion of an asset acquisition of AMP Therapeutics GmbH (“AMPT”), an anti-microbial peptide portfolio company of Boerhinger Ingelheim Venture Fund and Novartis Venture Fund. In connection with the acquisition, EnBiotix has established EnBiotix GmbH. EnBiotix has also initiated a collaboration with Leipzig University and AMPT’s scientific co-founder, Professor Ralf Hoffmann, Ph.D.

Full Press Release at BusinessWire | November 3rd, 2016

Elanco, EnBiotix Establish Collaboration Exploring Engineered Phage Technology

PRESS RELEASE | GREENFIELD, Ind. & CAMBRIDGE, Mass. – Today Elanco Animal Health, a division of Eli Lilly and Company, (NYSE: LLY) and EnBiotix, Inc., announced a collaboration to explore the application of EnBiotix’s engineered phage technology in specific animal health targets. If successful, this endeavor could result in potential alternatives for traditional antibiotics in animals.

This collaboration furthers Elanco’s commitment to aggressively seek and develop antibiotic alternatives as outlined in our comprehensive antibiotic stewardship plan,” said Jeff Simmons, President, Elanco Animal Health. “Innovative research will be key to protecting both human and animal health while safeguarding antibiotics for future generations.”

Full Press Release at BusinessWire | June 16th, 2016

EnBiotix to Collaborate with Mayo Clinic on Engineered Phage Program

PRESS RELEASE |CAMBRIDGE, Mass. – EnBiotix, Inc., a product-focused bioengineering company transforming and revitalizing existing antibiotic classes to combat the global rise of drug-resistant and drug-tolerant bacterial infections, today announced a new collaboration with Mayo Clinic to continue development of  the company’s drug candidate EPP-001, an engineered bacteriophage product to deliver biofilm dispersing enzymes to treat Staphylococcus aureus (S. aureus) infections in prosthetic joints. In addition, EnBiotix received a funding award from Mayo Clinic Ventures which is helping to facilitate the project. The research program team will be supervised by Robin Patel, M.D., Director, Infectious Diseases Research Laboratory, Mayo Clinic, and Chair, Division of Clinical Microbiology, Mayo Clinic and Govind Rajagopalan Ph.D., Associate Professor of Immunology, and conducted at both Mayo Clinic and EnBiotix laboratories. 

Full Press Release at BusinessWire| June 13th, 2016

EnBiotix, Inc. Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development

PRESS RELEASE | CAMBRIDGE, Mass.–EnBiotix, Inc. announced today that it is a Grand Challenges Explorations (“GCE”) winner, an initiative funded by the Bill & Melinda Gates Foundation. The EnBiotix team will pursue an innovative global health and development research project entitled “Integrated Systems Biology for Phage/Microbiome Modeling” for the generation and visualization of novel network models highlighting host-microbe interactions and the subnetworks most altered by phage therapy. The approach should yield an enhanced understanding of the effect of the gut microbiome on the development a variety diseases involving disruptions in the microbiome and ultimately aid in the development of precision phage therapies for environmental enteric dysfunction in children.

Full Press Release at BusinessWire| May 26th, 2016

EnBiotix Closes Series A Financing; Forms EnBiotix (Brasil) Ltda. in Deal with Wired Holdings

PRESS RELEASE | CAMBRIDGE, Mass.–EnBiotix, Inc., a product-focused bioengineering company transforming and revitalizing existing antibiotic classes to combat the global rise of drug-resistant and drug-tolerant bacterial infections, today announced the completion of a Series A financing. Investors in the round included Wired Holdings Investment Corp. (“WHIC”) and Apeiron Holdings Limited (“AHL”). In conjunction with the transaction, WHIC and EnBiotix, Inc. have entered into an agreement to establish a new joint venture company in Brazil, EnBiotix (Brasil) Ltda. (“EBL”), for the purposes of developing and commercializing EnBiotix’s product portfolio throughout Latin America. Roberto Guttman, Founder and CEO of Wired Holdings, has joined the EnBiotix Board of Directors.

Full Press Release at BusinessWire | May 12th, 2016

Massachusetts Life Sciences Center Announces New Round of Cooperative Research Matching Grants

June 26th, 2015

EnBiotix Scientific Founder James J. Collins, Ph.D., Elected to the National Academy of Sciences

PRESS RELEASE | EnBiotix is delighted to announce that its scientific founder and Chairman of its Scientific Advisory Board, Professor James J. Collins, was elected to the National Academy of Sciences on April 29, 2014. Dr. Collins is the William F. Warren Distinguished Professor, University Professor and Professor of Biomedical Engineering; Director, Center of Synthetic Biology, Boston University and the Wyss Institute for Biologically Inspired Engineering, Harvard University; and Investigator of the Howard Hughes Medical Institute. | May 1st, 2014